Synagis market growth outlook points to stronger RSV prevention demand

The Synagis market is expected to keep expanding through 2026 as RSV prevention, pediatric biologics and healthcare spending rise worldwide. North America led the market in 2025, while Europe is projected to grow fastest as preventive monoclonal antibodies gain traction.

Why it matters: - Synagis is used to help prevent serious RSV infections in high-risk infants and children, making the market important for pediatric respiratory care. - Rising RSV burden, higher healthcare spending and broader use of preventive biologics are increasing demand for monoclonal antibody-based prophylaxis. - The market outlook points to continued investment in next-generation RSV prevention therapies and longer-acting monoclonal antibodies.

What happened: - The Business Research Company published a 2026 Synagis market report covering competitors, key segments, regional trends and future growth through 2026. - The report says the Synagis market is experiencing notable growth tied to respiratory health needs in infants and children. - A free sample of the report is available here. - The full report is available here.

The details: - Synagis, also known as palivizumab, is a therapeutic monoclonal antibody designed to prevent lower respiratory tract infections caused by RSV. - The drug works by binding to RSV and blocking the virus from entering and infecting cells in the respiratory tract. - Historic growth was driven by higher RSV incidence in infants, greater awareness of preventive monoclonal antibody treatments, expansion of neonatal intensive care units, reimbursement options for RSV prophylaxis and regulatory approvals of pediatric biologics. - Forecast-period growth is expected to benefit from expanded biologic manufacturing, rising pediatric healthcare spending and broader use of precision immunotherapy methods. - Key trends highlighted in the report include wider use of monoclonal antibody-based RSV prophylaxis, more preventive pediatric immunotherapy, expanded cold-chain logistics for biologics, greater focus on high-risk infants and improved biologic manufacturing scalability. - The report says chronic respiratory diseases are a major growth driver because these conditions increase demand for preventive therapies in vulnerable pediatric populations. - The World Health Organization said in June 2025 that more than 80 million people have chronic respiratory diseases globally, with many cases undiagnosed. - UK healthcare expenditure rose 5.6% in nominal terms from 2022 to 2023, compared with 0.9% growth in 2022, according to the Office for National Statistics in May 2024.

Between the lines: - The market is being shaped by a shift from reactive treatment to prevention, especially for infants at highest risk of severe RSV complications. - Growing healthcare budgets and manufacturing capacity suggest the market is becoming more scalable, not just more clinically important. - Regional leadership in North America and faster growth in Europe point to a market that is still concentrated in mature healthcare systems.

What’s next: - The report expects demand to rise as investment in RSV prevention therapies continues and long-acting monoclonal antibodies gain attention. - Europe is projected to be the fastest-growing region during the forecast period. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa for a broader global view. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - North America held the largest market share in 2025, supported by established healthcare infrastructure and high adoption of monoclonal antibody therapies.

The bottom line: - Synagis remains a niche but growing pediatric prevention market, with RSV burden, reimbursement support and biologics innovation driving the next phase of expansion.